Amunix Pharmaceuticals, Inc.

When Marianne De Backer took the helm at San Francisco-based Vir Biotechnology in April 2023, the company was facing a dramatic shift in fortune. After riding high during the COVID-19 pandemic with bl

These are still heady days for the newly in-power Labour party, not yet passed the 100-day honeymoon period and not yet the target of too much criticism, which, history tells us, will not be too far a

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp